Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IQVIA : Collaborates with HealthCore to Advance Clinical Research Using Real-World Data

09/08/2021 | 08:14am EDT

IQVIA™ (NYSE: IQV) announces its strategic collaboration with HealthCore, Inc., a leading real world research organization in the United States, to advance real world evidence (RWE) studies with increased quality and efficiency. RWE studies incorporate innovative scientific methods with dynamic data from sources such as electronic medical records, pharmacy and medical claims, laboratory and genomics records, and patient-reported outcomes.

“IQVIA is excited to collaborate with HealthCore to enhance novel research designs and the impact of real world studies,” said Rob Kotchie, president, Real World Solutions at IQVIA. “Real world evidence is playing an increasingly important role in healthcare decision making. IQVIA is committed to enhancing evidence generation with the goal of advancing patient health and clinical outcomes.”

The IQVIA HealthCore agreement focuses on improving Real World Data (RWD) breadth and depth, as well as research innovation. Most HealthCore de-identified claims and clinical data have been incorporated into the IQVIA PharMetrics® Plus data source, resulting in a substantial patient volume increase. Voluntary patient participation allows linkage to other supported data sources, allowing a more complete view into the patient healthcare experience. Large data sources are key to answering complex patient research questions on topics such as clinical safety and comparative effectiveness.

This innovative research collaboration will focus specifically on real world studies such as external comparators, pragmatic trials, and enriched studies. Enriched study types often combine secondary data sources, along with primary data collection via chart reviews and other forms of physician or opt-in patient data collection, including patient-reported outcomes. With growing regulatory acceptance of RWE in clinical trials, there is increased interest in external comparator studies that utilize real world data sources as comparison arms in single-arm trials. HealthCore’s patient and physician networks support a more streamlined approach to these studies through chart reviews and information abstraction.

“We are so pleased to be working with IQVIA to enhance its data environment and further our relationship through collaboration on progressive research designs, such as synthetic control arm studies, pragmatic clinical trials, decentralized clinical trials and COVID-19 focused research,” said Mark Cziraky, president, HealthCore.

About HealthCore, Inc.

HealthCore is finding evidence and truth at the core of healthcare. We work with life sciences companies, government agencies, payors, and collaborators on a broad range of research services focused on informing key decision makers. As a wholly owned, independently operating subsidiary of Anthem, Inc., we utilize a powerful research ecosystem of expertise, relationships, and data to generate the evidence needed to improve healthcare. To learn more about HealthCore, visit www.HealthCore.com.


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 74,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

ę Business Wire 2021
All news about IQVIA HOLDINGS INC.
10/25IQVIA : Barclays Adjusts IQVIA Holdings' Price Target to $287 from $285, Keeps Overweight ..
10/22IQVIA : Morgan Stanley Adjusts Price Target on IQVIA Holdings to $290 from $280, Keeps Ove..
10/22IQVIA : Management's Discussion and Analysis of Financial Condition and Results of Operati..
10/21IQVIA : Q3 2021 IQVIA Earnings Conference Call Presentation
10/21Health Care Stocks Steady Pre-Bell Thursday
10/21IQVIA : Q3 Adjusted Earnings, Revenue Rise; Issues Q4 Outlook; Raises Full-Year 2021 Guida..
10/21IQVIA : Q3 Earnings Snapshot
10/21IQVIA : Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance - Form 8-K
10/21IQVIA HOLDINGS INC. : Results of Operations and Financial Condition (form 8-K)
10/21IQVIA : Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 13 827 M - -
Net income 2021 907 M - -
Net Debt 2021 10 665 M - -
P/E ratio 2021 55,0x
Yield 2021 -
Capitalization 48 923 M 48 923 M -
EV / Sales 2021 4,31x
EV / Sales 2022 3,91x
Nbr of Employees 77 000
Free-Float 74,2%
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 18
Last Close Price 256,09 $
Average target price 285,94 $
Spread / Average Target 11,7%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
W. Richard Staub President-Research & Development Solutions
Kevin C. Knightly President-Technology & Commercial Solutions
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
SEAGEN INC.0.22%31 933
CELLTRION, INC.-38.02%25 328